|
3.1 Tabac
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Horizon to Advance Redx's Pan-RAF Inhibitors against Cancer [GEN]
|
|
|
|
|
|
Horizon
Discovery Group will join Redx Pharma in advancing the latter’s
pan-rapidly accelerated fibrosarcoma (pan-RAF) inhibitor program, with
future licensing for colorectal cancer and other oncology indications to
a big pharma in mind, the companies said today.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Twenty-three therapies axed from Cancer Drugs Fund [PharmaTimes]
|
|
|
|
|
|
the
distressing de-listing process could have been avoided “if NICE and NHS
England had transitioned earlier to a more appropriate, sustainable
solution for evaluating and approving cancer medicines for routine use,”
argues Alison Clough, the Association of the British Pharmaceutical
Industry’s acting chief executive.
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
World Conference on Lung Cancer Opens with Focus on Global Collaboration [Colorado Cancer Blogs]
|
|
|
|
|
|
“We
all share one goal: conquering the lung and thoracic cancers that
account for nearly a third of all cancer deaths worldwide – more than
breast, prostate and colon cancers combined,” said Dr. Fred R. Hirsch,
CEO of the International Association for the Study of Lung Cancer
(IASLC), University of Colorado Cancer Center member, professor of
Medicine and Pathology at the University of Colorado School of Medicine
and Conference President.
|
|
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|